Microglia is a key player in the reduction of stroke damage promoted by the new antithrombotic agent ticagrelor

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 6, 2014, Pages 979-988

  Gelosa, Paolo ^a   Lecca, Davide ^a   Fumagalli, Marta ^a   Wypych, Dorota ^a,b   Pignieri, Alice ^a   Cimino, Mauro ^c   Verderio, Claudia ^d   Enerbäck, Malin ^e   Nikookhesal, Elham ^e   Tremoli, Elena ^a,f   Abbracchio, Maria P ^a   Sironi, Luigi ^a,f  

^a UNIVERSITY OF MILAN   (Italy)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c UNIVERSITY OF URBINO   (Italy)

^d CNR   (Italy)

^e ASTRAZENECA R AND D   (Sweden)

^f CENTRO CARDIOLOGICO MONZINO   (Italy)

Author keywords

microglia; middle cerebral artery occlusion; rat; ticagrelor

Indexed keywords

ADENOSINE DIPHOSPHATE; CHEMOKINE RECEPTOR CX3CR1; GREEN FLUORESCENT PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PHARMACOLOGICAL BIOMARKER; PROTEIN ED 1; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CELL INFILTRATION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG BLOOD LEVEL; DRUG MECHANISM; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MALE; MEDIATOR RELEASE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SCORING SYSTEM; SPRAGUE DAWLEY RAT; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE; ANIMALS; BRAIN ISCHEMIA; CHEMOKINE CCL2; ECTODYSPLASINS; FIBRINOLYTIC AGENTS; INTERLEUKIN-1; MICE; MICE, TRANSGENIC; MICROGLIA; NERVE TISSUE PROTEINS; NITRIC OXIDE SYNTHASE TYPE II; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; STROKE; TIME FACTORS;

EID: 84901829182     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2014.45     Document Type: Article

References (29)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C et al. International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006; 58: 281-341. (Pubitemid 44394905)
2. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207. (Pubitemid 32144286)
3. Nawarskas JJ, Clark SM. Ticagrelor: A novel reversible oral antiplatelet agent. Cardiol Rev 2011; 19: 95-100.
4. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Tica-grelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
5. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB et al. The p2y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 2006; 9: 1512-1519. (Pubitemid 44862659)
6. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl- leukotrienes receptor. EMBO J 2006; 25: 4615-4627. (Pubitemid 44498134)
7. Zhao B, Zhao CZ, Zhang XY, Huang XQ, Shi WZ, Fang SH et al. The new P2Y-like receptor g protein-coupled receptor 17 mediates acute neuronal injury and late microgliosis after focal cerebral ischemia in rats. Neuroscience 2012; 202: 42-57.
8. Fumagalli M, Lecca D, Abbracchio MP. Role of purinergic signalling in neuro-immune cells and adult neural progenitors. Front Biosci 2011; 16: 2326-2341.
9. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-4114. (Pubitemid 30314508)
10. Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003; 23: 322-327. (Pubitemid 36231947)
11. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia 2013; 61: 827-842.
12. Villa P, Triulzi S, Cavalieri B, Di Bitondo R, Bertini R, Barbera S et al. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol Med 2007; 13: 125-133. (Pubitemid 46944954)
13. Sironi L, Mitro N, Cimino M, Gelosa P, Guerrini U, Tremoli E et al. Treatment with LXR agonists after focal cerebral ischemia prevents brain damage. FEBS Lett 2000; 582: 3396-3400.
14. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Academic Press: San Diego, CA, 2007.
15. Paxinos G, Franklin KBJ. Mouse brain in stereotaxic coordinates. Academic Press: San Diego, CA, 2001.
16. Honda S, Sasaki Y, Ohsawa K, Imai Y, Nakamura Y, Inoue K et al. Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors. J Neurosci 2001; 21: 1975-1982. (Pubitemid 32221381)
17. Lee S, Chung CY. Role of VASP phosphorylation for the regulation of microglia chemotaxis via the regulation of focal adhesion formation/maturation. Mol Cell Neurosci 2009; 42: 382-390.
18. Lee SH, Hollingsworth R, Kwon HY, Lee N, Chung CY. b-Arrestin 2-dependent activation of ERK1/2 is required for ADP-induced paxillin phosphorylation at Ser(83) and microglia chemotaxis. Glia 2012; 60: 1366-1377.
19. Gill R, Sibson NR, Hatfield RH, Burdett NG, Carpenter TA, Hall LD et al. A comparison of the early development of ischaemic damage following permanent middle cerebral artery occlusion in rats as assessed using magnetic resonance imaging and histology. J Cereb Blood Flow Metab 1995; 15: 1-11.
20. Ceruti S, Villa G, Genovese T, Mazzon E, Longhi R, Rosa P et al. The P2Y-like receptor GPR17 as a sensor of damage and a new potential target in spinal cord injury. Brain 2009; 132: 2206-2218.
21. Webster CM, Hokari M, McManus A, Tang XN, Ma H, Kacimi R et al. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS ONE 2013; 8: e70927.
22. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost 2010; 104: 609-617.
23. Pál G, Vincze C, Renner É, Wappler EA, Nagy Z, Lovas G et al. Time course, distribution and cell types of induction of transforming growth factor betas following middle cerebral artery occlusion in the rat brain. PLoS ONE 2012; 7: e46731.
24. De Simone R, Niturad CE, De Nuccio C, Ajmone-Cat MA, Visentin S, Minghetti L. TGF-b and LPS modulate ADP-induced migration of microglial cells through P2Y1 and P2Y12 receptor expression. J Neurochem 2010; 115: 450-459.
25. Orr AG, Orr AL, Li XJ, Gross RE, Traynelis SF. Adenosine A(2A) receptor mediates microglial process retraction. Nat Neurosci 2009; 12: 872-878.
26. Prinz M, Priller J. Tickets to the brain: role of CCR2 and CX3CR1 in myeloid cell entry in the CNS. J Neuroimmunol 2010; 224: 80-84.
27. Martini C, Daniele S, Trincavelli ML, Lecca D, Panighini A, Abbracchio MP. The oral reversibly-binding antiplatelet agent, Ticagrelor, acts as an antagonist at the P2Y-like receptor GPR17. Purinerg Signal 2010; 6: 162-162.
28. Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M et al. The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS ONE 2008; 3: e3579.
29. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, van Giezen JJ, Jonasson J, Nylander S et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol 2013; 61: 723-727.